Edwards Lifesciences Corporation

EW Healthcare Medical Devices

Edwards Lifesciences Corporation’s revenue for fiscal 2025 (year ended December 2025) was $6.1 billion, up 11.5% from fiscal 2024.

Revenue
+10.5%
EPS
+6.00%
Free cash flow
−1.84%
Total debt
+0.10%

Quarter to September 2026, against a year earlier

101.50 0.68 +0.67%
Market cap
$58.1B
P/E
56.7×
Fwd P/E
36.5×
Dividend yield
—
F-score
5/9
Altman Z
11.54
Beneish M
−2.48
Dividend safety
n/a

Edwards Lifesciences Corporation 10-Q filed Jul 31, 2024

Fiscal Q2 2024 · Period ended Jun 30, 2024 · Filed · accepted 4:14 PM ET · Document on sec.gov · Filing index

Nothing in this filing raised a red flag. The document itself is on sec.gov.

Read the filing on sec.gov